Science

Heidi Ko: Our latest mini-review on HER2 as a tumor-agnostic biomarker

Heidi Ko/LinkedIn

Mar 4, 2025, 11:22

Heidi Ko: Our latest mini-review on HER2 as a tumor-agnostic biomarker

Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared an article on LinkedIn:

“Excited to share that our latest mini-review on HER2 as a tumor-agnostic biomarker is now published in Frontiers in Oncology!

We delved into the evolving role of HER2 overexpression in various solid tumors and discussed how advancements in Antibody Drug Conjugates, particularly T-DXd, are transforming treatment strategies in solid malignancies.

We also addressed the challenges in HER2 testing across pan solid tumors and the potential of NGS and AI algorithms to enhance diagnostic accuracy.

Check out the full article here.”

From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates.

Authors: Heidi C Ko, et al.

More posts featuring Heidi Ko.

antibody biomarker cancer fight against cancer Frontiers in Oncology Global fight against cancer Heidi Ko HER2 Labcorp Drug Development OncoDaily Oncology T-Dxd

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer